A study on the immune response and safety of a vaccine against respiratory syncytial virus given to adults 50-59 years of age, including adults at increased risk of respiratory syncytial virus lower respiratory tract disease, compared to older adults 60 years of age and above

Trial Identifier: 219238
Sponsor: GlaxoSmithKline
Start Date: October 2022
Primary Completion Date: March 2023
Study Completion Date: February 2024
Condition: Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

No locations posted.